Company: PSTV
Filing Date: 2025-08-14
Form Type: 8-K
Source: 0001193125-25-180814
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

As previously reported, on June 3, 2025, the Nasdaq Listing Qualifications Department (the “ Staff”) notified Plus Therapeutics, Inc. (the “ Company”) that, as of March 31, 2025, the Company no longer satisfied Nasdaq Listing Rule 5550(b)(1), which requires certain companies listed on The Nasdaq Capital Market (“ Nasdaq”) to maintain a minimum of $2.5 million in stockholders’ equity (the “ Equity Rule”). Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March 6, 2026, with respect to the Equity Rule in particular, the Staff issued a delist determination following such non-compliance. On June 10, 2025, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “ Panel”), which stayed any further action by the Staff. The hearing was held on July 15, 2025.

As previously disclosed, on July 22, 2025, the Company was notified by Nasdaq that the Panel had granted the Company’s request for an extension to evidence compliance with the Equity Rule subject to the Company’s satisfaction of certain conditions.

As reflected in the Form10-Qfor the quarter ended June 30, 2025 filed today, the Company reported stockholders’ equity of $3 million and therefore satisfied the Equity Rule as of June 30, 2025.

Furthermore, since June 30, 2025, the Company has sold over $2 million in common stock pursuant to its newly established $50.0 million equity line of credit (“ ELOC”) with Lincoln Park Capital Fund, LLC. The issuance of shares pursuant to the ELOC was approved by the Company’s shareholders at a meeting on August 7, 2025. Based upon those sales and as set forth in the unaudited pro forma balance sheet filed herewith as Exhibit 99.1, the Company continues to report stockholders’ equity of at least $2.5 million as of the date of this filing. The Company awaits Nasdaq’s confirmation that it has evidenced compliance with the Equity Rule.

Additionally, as of the close of business on August 13, 2025, the Company reported a market value of listed securities (“ MVLS”) of at least $35 million, which is an alternative threshold for compliance under Nasdaq